vTv Therapeutics Inc. 2025 Annual Report: Key Investor Insights

1. Company Overview and Key Developments

vTv Therapeutics Inc. (“vTv” or the “Company”), headquartered in High Point, North Carolina, is a clinical-stage pharmaceutical company focusing on the discovery and development of orally administered small molecule drug candidates to address unmet medical needs. The Company’s primary research and development efforts are centered around metabolic and inflammatory diseases.

2. Major Price-Sensitive Highlights

Private Placement Raises Up to \$200 Million

• In September 2025, vTv Therapeutics completed a major private placement of its Class A common stock and pre-funded warrants, raising approximately \$80 million in gross proceeds upfront. Additionally, investors received warrants exercisable at a 50% premium, making the total potential proceeds from the placement up to \$200 million.
• This substantial capital injection provides the Company with the necessary funding to advance its lead program, cadisegliatin (also known as TTP399), a novel, oral, liver-selective glucokinase activator, into further stages of clinical development.
• The size and terms of this financing are significant, reflecting strong investor confidence and providing a potential catalyst for share price appreciation should clinical milestones be met.

Advancement of Lead Program: Cadisegliatin (TTP399)

• The Company’s lead drug candidate, cadisegliatin (TTP399), is highlighted as a novel, oral, liver-selective glucokinase activator. This compound is being developed for the treatment of type 1 diabetes and potentially other metabolic disorders.
• The capital from the private placement will be used to continue and potentially accelerate the clinical development of cadisegliatin, which stands as a critical value driver for the Company.
• Any positive clinical or regulatory developments regarding cadisegliatin could have a significant impact on shareholder value.

Key Strategic Transactions

• The Company entered into a Common Stock Purchase Agreement with G42 Investments in May 2022, under which G42 purchased 259,657 shares for \$25 million (half paid in cash, half in a promissory note). The agreement includes transfer restrictions and registration rights for G42, suggesting a stable and supportive investor relationship.

3. Important Shareholder Information

• Share Structure (as of March 10, 2026):
  • Class A Common Stock Outstanding: 3,938,654 shares
  • Class B Common Stock Outstanding: 241 shares

  The relatively low number of shares outstanding could amplify the price impact of any material news or trading activity.

• Listing: vTv’s Class A Common Stock is listed on the Nasdaq Capital Market under the symbol VTVT.
• Corporate Status: The Company is a non-accelerated filer and a smaller reporting company, which may impact its regulatory filing obligations and investor disclosures.
• No Indication of Shell Company Status: The Company is not a shell company, and there are no restatements or corrections to previously issued financial statements.
• Upcoming Catalysts: Portions of the Company’s definitive proxy statement for the 2026 Annual Meeting of Stockholders will be filed within 120 days of December 31, 2025, and may contain further details relevant for governance and compensation matters.

4. Forward-Looking Statements and Risks

The report contains forward-looking statements regarding the Company’s future plans, strategies, potential market opportunities, and clinical development results. Shareholders should note that actual results may differ materially due to risks discussed in the report, including clinical trial outcomes, regulatory changes, and competition.

5. Analyst Takeaways

• The \$80-200 million private placement provides the Company with a strong financial runway, supporting the ongoing development of cadisegliatin.
• Any significant clinical progress or regulatory milestones with cadisegliatin could be highly price-sensitive and may drive substantial share price movements.
• Key strategic partnerships, such as with G42 Investments, provide validation and potential for future financial and strategic support.
• With a focused pipeline and strong recent financing, vTv Therapeutics is well-positioned for potential value creation, but shareholders should remain alert to clinical and regulatory risks.

Potential Share Price Catalysts:

• Clinical trial results or regulatory updates concerning cadisegliatin (TTP399)
• Further capital raises or new strategic partnerships
• Changes in competitive landscape or industry developments in metabolic disease treatments

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. The information is based on the Company’s 2025 Annual Report and may be subject to change. The Company’s future performance is subject to various risks and uncertainties, including but not limited to those described in the “Risk Factors” section of the report.

View vTv Therapeutics Inc. Historical chart here